Charles River Laboratories International, Inc.
CRL
$162.85
-$5.84-3.46%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.18% | -0.83% | -0.49% | 0.59% | -2.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18% | -0.83% | -0.49% | 0.59% | -2.71% |
| Cost of Revenue | 4.46% | -2.56% | 1.67% | -1.49% | -2.23% |
| Gross Profit | -5.02% | 2.87% | -4.25% | 4.30% | -3.59% |
| SG&A Expenses | -15.43% | -0.63% | -7.30% | 12.04% | -0.51% |
| Depreciation & Amortization | -48.44% | 123.21% | -15.43% | -10.73% | 16.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.52% | 3.50% | -0.92% | 0.83% | -1.32% |
| Operating Income | 18.33% | -47.39% | 2.05% | -0.62% | -10.70% |
| Income Before Tax | -183.22% | -35.66% | -4.43% | -40.31% | -63.66% |
| Income Tax Expenses | -249.90% | -485.05% | 51.07% | -26.26% | -58.82% |
| Earnings from Continuing Operations | -157.20% | -29.26% | -20.97% | -44.10% | -65.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 89.98% | 64.57% | -77.74% | -103.89% | 73.13% |
| Net Income | -158.28% | -28.93% | -21.87% | -44.38% | -65.09% |
| EBIT | 18.33% | -47.39% | 2.05% | -0.62% | -10.70% |
| EBITDA | 6.14% | 12.90% | -30.05% | 26.18% | -9.67% |
| EPS Basic | -160.33% | -33.22% | -17.25% | -39.01% | -61.60% |
| Normalized Basic EPS | -90.65% | -10.95% | -11.29% | 6.31% | -20.38% |
| EPS Diluted | -160.64% | -33.22% | -17.29% | -39.08% | -61.53% |
| Normalized Diluted EPS | -90.61% | -10.95% | -11.35% | 6.56% | -20.13% |
| Average Basic Shares Outstanding | -3.41% | -3.76% | -4.24% | -4.66% | -1.48% |
| Average Diluted Shares Outstanding | -3.74% | -3.76% | -4.18% | -4.88% | -1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |